NCT00495144已完成1 期
A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 129
- 试验地点
- 14
- 主要终点
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of TH-302 administered weekly x 3, repeated every 4 weeks in patients with advanced solid tumors
研究概览
简要总结
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors. The study is designed to establish the safety including the maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of TH-302.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age
- •Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee
- •Histologically or cytologically confirmed advanced or metastatic solid malignancy
- •Advanced or metastatic solid malignancy previously treated with one or more regimens of chemotherapy or for which no effective therapy is available
- •Recovered from toxicities of prior therapy
- •Measurable disease by RECIST criteria (at least one target lesion)
- •ECOG performance status of 0 or 1
- •Life expectancy of at least 3 months
- •Acceptable liver function:
- •Bilirubin ≤ 1.5 times upper limit of normal
- •AST (SGOT) and ALT (SGPT) ≤ 2.5 times upper limit of normal (ULN); if liver metastases are present, then ≤ 5 x ULN is allowed
- •Acceptable renal function:
- •Serum creatinine ≤ ULN
- •Acceptable hematologic status (without hematologic support):
- •ANC ≥ 1500 cells/μL
- •Platelet count ≥ 100,000/μL
- •Hemoglobin ≥ 9.0 g/dL
- •Urinalysis: No clinically significant abnormalities
- •Acceptable coagulation status:
- •PT ≤ 1.3 x ULN
- •PTT ≤ 1.3 x ULN
- •All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose
排除标准
- •Prior treatment with high dose chemotherapy
- •Prior radiotherapy to more than 25% of the bone marrow
- •New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, or unstable arrhythmia
- •Seizure disorders requiring anticonvulsant therapy
- •Symptomatic brain metastases (unless previously treated and well controlled for a period of ≥ 3 months)
- •Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the investigator any physiological state leading to hypoxemia
- •Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
- •Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- •Treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.) or hormones within 4 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C)
- •Patients who participated in an investigational drug or device study within 28 days prior to study entry
- •Known infection with HIV, hepatitis B, or hepatitis C
- •Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation (containing solutol and/or propylene glycol)
- •Females who are pregnant or breast-feeding
- •Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- •Unwillingness or inability to comply with the study protocol for any reason
结局指标
主要结局
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of TH-302 administered weekly x 3, repeated every 4 weeks in patients with advanced solid tumors
次要结局
- To establish the pharmacokinetics of intravenously administered TH-302
- To assess the anti-tumor activity of TH-302 as measured by objective response and duration of response
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsAdvanced Solid TumorNCT05001516Turning Point Therapeutics, Inc.17
招募中
1 期
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid TumorsSolid Tumor, AdultPancreatic Ductal AdenocarcinomaColorectal CancerNCT06598007Crossignal Therapeutics, Inc.78
招募中
1 期
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 MutationsNSCLC (Advanced Non-small Cell Lung Cancer)NCT06706076BlossomHill Therapeutics675
已完成
2 期
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell DiseaseSickle Cell DiseaseNCT00445978BioMarin Pharmaceutical32
招募中
1 期
A Study of DB-1310 in Advanced/Metastatic Solid TumorsAdvanced Solid TumorNCT05785741DualityBio Inc.1,000